prenalterol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
bronchodilators, phenethylamine derivatives	2258	57526-81-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: prenalterol (S)-Prenalterol (-)-Prenalterol S-Varbian	A partial adrenergic agonist with functional beta 1-receptor specificity and inotropic effect. It is effective in the treatment of acute CARDIAC FAILURE, postmyocardial infarction low-output syndrome, SHOCK, and reducing ORTHOSTATIC HYPOTENSION in the SHY-RAGER SYNDROME. Molecular weight: 225.29 Formula: C12H19NO3 CLOGP: 1.09 LIPINSKI: 0 HAC: 4 HDO: 3 TPSA: 61.72 ALOGS: -1.94 ROTB: 6

Molecule

Description

Molfile Inchi Smiles

Synonyms:

prenalterol
(S)-Prenalterol
(-)-Prenalterol
S-Varbian

A partial adrenergic agonist with functional beta 1-receptor specificity and inotropic effect. It is effective in the treatment of acute CARDIAC FAILURE, postmyocardial infarction low-output syndrome, SHOCK, and reducing ORTHOSTATIC HYPOTENSION in the SHY-RAGER SYNDROME.

Molecular weight: 225.29
Formula: C12H19NO3
CLOGP: 1.09
LIPINSKI: 0
HAC: 4
HDO: 3
TPSA: 61.72
ALOGS: -1.94
ROTB: 6

Drug dosage:

Dose	Unit	Route
10	mg	P

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.48 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	33 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	4.28 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	22.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.85 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1980	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C01CA13	CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES Adrenergic and dopaminergic agents
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D000322	Adrenergic Agonists
MeSH PA	D058665	Adrenergic beta-1 Receptor Agonists
MeSH PA	D000318	Adrenergic beta-Agonists
MeSH PA	D002316	Cardiotonic Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D020011	Protective Agents
MeSH PA	D013566	Sympathomimetics

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.48	acidic
pKa2	9.19	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN		Ki	6.60		WOMBAT-PK
Beta-2 adrenergic receptor	GPCR		ADRB2_BOVIN		Kd	5.97		CHEMBL

External reference:

ID	Source
C0033051	UMLSCUI
CHEBI:8391	CHEBI
CHEMBL1160714	ChEMBL_ID
DB13777	DRUGBANK_ID
D011294	MESH_DESCRIPTOR_UI
42396	PUBCHEM_CID
537	IUPHAR_LIGAND_ID
4121	INN_ID
M4G34404CX	UNII

Pharmaceutical products:

None